A Phase 2 interventional study of SKY0402 and Bupivacaine HCl in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 246th largest by enrollment, is one of 2 that started in 2005, is one of 43 in phase 2, and was the 21st registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
25 studies in Pain, Postoperative by Pacira BioSciences, Inc.: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 25 studies in Pain, Postoperative by Pacira BioSciences, Inc., this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 2, and was the 11th registered.
Pacira BioSciences, Inc.’s Pain, Postoperative studies by the year they started, since 2004.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Pacira BioSciences, Inc.’s 25 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to determine the appropriate dose of SKY0402 administered as a nerve block for the management of postoperative pain following bunionectomy.
This Phase 2, multicenter, randomized, double blind, dose escalating/de-escalating study evaluated the safety, efficacy, and pharmacokinetics of a single dose of SKY0402 compared to a single 125 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects undergoing bunionectomy.
Up to 88 subjects were to be randomized in five consecutive cohorts. The dose of bupivacaine HCl (125 mg) was to remain constant for all cohorts. After completion of Cohort 1, the decision to increase or decrease the dose of SKY0402 was made by a Cohort Data Review Committee following a review of pharmacokinetic, safety, and selected efficacy data from the previous cohort.
Study drug was to be administered as an ankle block, with or without a tourniquet, between 1 hour before the induction of general anesthesia and 20 minutes before the end of general anesthesia. The ankle block procedure consisted of five injections via three skin entries targeting the following nerves: posterior tibial, sural, deep peroneal, superficial peroneal, and saphenous.
The use of intravenous fentanyl during general anesthesia was permitted, but was not to exceed 250 micrograms. The intraoperative use of morphine was prohibited. Postoperatively, subjects had access to both opioid and non-opioid supplemental pain medication under general guidelines. Blood samples for the determination of plasma bupivacaine concentrations were obtained at Baseline and at specified time points through 96 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects were eligible for enrollment if they met the following criteria:
Scheduled to undergo a primary unilateral first metatarsal bunionectomy repair under general anesthesia, with or without internal fixation.
NOTE: For the purpose of this protocol, all surgical procedures involving osteotomy of the first metatarsal (significant bone resection, excision, surgical fracture, etc.) or fusion of the first metatarsal phalangeal joint were considered qualified procedures, whether or not performed specifically to repair a bunion (hallus valgus deformity). Surgical techniques accompanied by minimal bone excision (e.g. cheilectomy) or procedures limited to soft tissue repair were not eligible for this study.
Exclusion Criteria:
Subjects were excluded from the study if they met any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low-dose (175 mg), low-mid dose( 225 mg), and mid-dose (350 mg)
Drug: SKY0402
Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
Drug: Bupivacaine HCl
Single dose of SKY0402 administered as a nerve block
Single dose of 125 mg administered as a nerve block
Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain
The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.
Time frame: Through 96 hours postdose
Number of Patients With Adverse Events
All adverse events were to be recorded from the time of dosing through Day 8. Serious adverse events (SAEs) were to be recorded through Day 30.
Time frame: Through 30 days postdose
| Milestone | SKY0402 | Bupivacaine HCl |
|---|---|---|
| Started | 38 | 20 |
| Completed | 38 | 20 |
| Not completed | 0 | 0 |
The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.
| hours | Bupivacaine HCl | SKY0402 Low Dose (175 mg) | SKY0402 Low-Mid Dose (225 mg) | SKY0402 Mid Dose (350 mg) |
|---|---|---|---|---|
| Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain | 9.4 (6.1 to 11.2) | 1.9 (0.3 to 9.0) | 1.2 (0.6 to 5.4) | 2.4 (0.3 to 8.3) |
All adverse events were to be recorded from the time of dosing through Day 8. Serious adverse events (SAEs) were to be recorded through Day 30.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SKY0402 | — | 1/38 (2.6%) | 15/38 (39.5%) |
| Bupivacaine HCl | — | 0/20 (0%) | 6/20 (30%) |
| Event | SKY0402 | Bupivacaine HCl |
|---|---|---|
| Immobiliaztion prolongedInjury, poisoning and procedural complications | 1/38 | 0/20 |
| Event | SKY0402 | Bupivacaine HCl |
|---|---|---|
| NauseaGastrointestinal disorders | 9/38 | 3/20 |
| HypotensionVascular disorders | 0/38 | 3/20 |
| VomitingGastrointestinal disorders | 3/38 | 0/20 |
| BradycardiaCardiac disorders | 2/38 | 0/20 |
| ConstipationGastrointestinal disorders | 2/38 | 0/20 |
| HeadacheNervous system disorders | 2/38 | 0/20 |
| Age, Categorical(Participants) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 15 | 44 |
| >=65 years | 9 | 5 | 14 |
| Age, Continuous(years) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| Mean | 54.3 ± 14.04 | 55.7 ± 14.22 | 54.8 ± 14.1 |
| Sex: Female, Male(Participants) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| Female | 30 | 18 | 48 |
| Male | 8 | 2 | 10 |
| Region of Enrollment(participants) | SKY0402 | Bupivacaine HCl | Total |
|---|---|---|---|
| Australia | 3 | 5 | 8 |
| Belgium | 29 | 12 | 41 |
| United Kingdom | 3 | 2 | 5 |
| Netherlands | 3 | 1 | 4 |
No study locations are listed for this record.
The record gives a start of Mar 2005, a primary completion of Mar 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 6 years 2 months after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine